Cargando…
Identifying novel SMYD3 interactors on the trail of cancer hallmarks
SMYD3 overexpression in several human cancers highlights its crucial role in carcinogenesis. Nonetheless, SMYD3 specific activity in cancer development and progression is currently under debate. Taking advantage of a library of rare tripeptides, which we first tested for their in vitro binding affin...
Autores principales: | Fasano, Candida, Lepore Signorile, Martina, De Marco, Katia, Forte, Giovanna, Sanese, Paola, Grossi, Valentina, Simone, Cristiano |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Research Network of Computational and Structural Biotechnology
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9039736/ https://www.ncbi.nlm.nih.gov/pubmed/35495117 http://dx.doi.org/10.1016/j.csbj.2022.03.037 |
Ejemplares similares
-
The chromatin remodeling factors EP300 and TRRAP are novel SMYD3 interactors involved in the emerging ‘nonmutational epigenetic reprogramming’ cancer hallmark
por: Fasano, Candida, et al.
Publicado: (2023) -
SMYD3 Modulates the HGF/MET Signaling Pathway in Gastric Cancer
por: De Marco, Katia, et al.
Publicado: (2023) -
SMYD3 Modulates AMPK-mTOR Signaling Balance in Cancer Cell Response to DNA Damage
por: Lepore Signorile, Martina, et al.
Publicado: (2023) -
APC Splicing Mutations Leading to In-Frame Exon 12 or Exon 13 Skipping Are Rare Events in FAP Pathogenesis and Define the Clinical Outcome
por: Disciglio, Vittoria, et al.
Publicado: (2021) -
Chasing the FOXO3: Insights into Its New Mitochondrial Lair in Colorectal Cancer Landscape
por: Grossi, Valentina, et al.
Publicado: (2019)